<DOC>
	<DOCNO>NCT02806505</DOCNO>
	<brief_summary>This study evaluate safety efficacy peginterferon alfa-2a monotherapy participant Chronic Hepatitis C ( CHC ) End-Stage Renal Disease ( ESRD ) undergo hemodialysis .</brief_summary>
	<brief_title>HELPS Study - A Study Peginterferon Alfa-2a ( Pegasys ) Patients With Chronic Hepatitis C ( CHC ) End-Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Serum hepatitis C virus ribonucleic acid ( HCV RNA ) quantifiable great ( &gt; ) 600 IU/mL Liver biopsy consistent chronic hepatitis C infection obtain within 2 year enrollment Compensated liver disease without cirrhosis Participants endstage renal disease undergoing hemodialysis Negative serum pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug All fertile participant must use effective contraception treatment study drug Interferon therapy previous time Liver cirrhosis Signs symptom hepatocellular carcinoma History evidence decompensated liver disease Any investigational drug less equal 6 week prior first dose study drug History evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) Poorly control diabetes Thyroid dysfunction adequately control Evidence severe retinopathy clinically relevant ophthalmological disorder Severe hyperparathyroidism define intact Parathyroid Hormone ( PTH ) &gt; 800 picogram/milliliter ( pg/mL ) Therapy systemic antiviral , antineoplastic immunomodulatory treatment â‰¤ 6 month prior first dose study drug Acute renal failure Women ongoing pregnancy breast feed Positive test screen antiHAV IgM Ab ( hepatitis A virus immunoglobulin M antibody ) , hepatitis B surface antigen ( HBsAg ) , antiHBc ( hepatitis B core ) IgM Ab , antiHIV ( human immunodeficiency virus ) Ab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>